Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate January 2, 2018 • admin • Funding, General News, Grants, Pharmaceuticals Read More »
Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO June 16, 2017 • admin • General News, Military, Pharmaceuticals Read More »
FDA agrees that Countervail’s non-human primate animal model is appropriate for the company’s Animal Rule pivotal GLP study testing February 15, 2017 • admin • General News, Pharmaceuticals, Regulatory Read More »
Countervail Corporation’s Pre-proposal Accepted by NINDS CounterACT October 7, 2016 • admin • Grants, Pharmaceuticals Read More »
Countervail Presents at Annual CounterACT Meeting June 15, 2016 • admin • Pharmaceuticals Read More »
Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded. February 21, 2016 • admin • General News, Military, Pharmaceuticals Read More »
US Patent application submitted for novel OP Exposure Diagnostic Test. June 23, 2015 • admin • General News, Pharmaceuticals Read More »
Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »
Countervail holds second pre-IND meeting with Neurology Division of the FDA for guidance on development of a neuroprotectant against nerve agent exposure. February 20, 2015 • admin • General News, Pharmaceuticals Read More »
European patent for the use of galantamine as Method of Treating Organophosphorus Poisoning was granted and registered in Germany, Italy, France, UK, Spain, Turkey, Austria, Poland and Sweden. August 13, 2014 • admin • Agriculture, Military, Pharmaceuticals Read More »